In France,<\/strong> less than 1.5% of eligible patients will benefit from telemonitoring by the end of 2024. Two years after it became common law. <\/p>\n\n In Germany:<\/strong> 300,000 prescriptions. 56 applications reimbursed. 80 million budget by 2024. Sevenfold increase since 2021.<\/strong><\/p>\n\n This difference is no mere detail.<\/strong> It’s a signal: organization, not technology, determines success.<\/p>\n\n First, let’s look at the French context.<\/strong><\/p>\n\n Remote monitoring covers only six pathologies: heart failure, renal failure, respiratory failure, diabetes, cardiac prostheses and oncology. This list comes from the ETAPES experiment (2018-2023).<\/strong><\/p>\n\n The advantage:<\/strong> solid scientific basis. The problem:<\/strong> narrow market potential. Very narrow. <\/p>\n\n Next, let’s talk about compensation.<\/strong> Dual system :<\/p>\n\n Theoretically?<\/strong> Viable. Really?<\/strong> Access criteria are labyrinthine.<\/p>\n\n For “level 2 increased” heart failure (70\u20ac), you need precise combos<\/strong>: age, comorbidities, very specific clinical situations. This administrative granularity ensures rigor.<\/strong> But it also hinders professionals.<\/p>\n\n Air Liquide has left the French market. It’s revealing.<\/strong><\/p>\n\n The SNITEM declared: “outdated evaluation criteria, designed for yesterday’s medicine.”<\/strong> Traditional methodologies don’t match digital devices.<\/strong> Period.<\/p>\n\n Germany, on the other hand, has opted for “fast-track”.<\/strong><\/p>\n\n The program DiGA (Digital Health Applications)<\/a><\/strong> BfArM evaluates in 3 months maximum<\/strong>. Provisional registration? 12 months while you collect the real data.<\/strong><\/p>\n\n Result:<\/strong> 73 million policyholders benefit from rapid access to innovations. Secure framework maintained.<\/strong><\/p>\n\n The therapeutic spectrum has broadened considerably<\/strong>: 53% of DiGAs treat mental illnesses. 11% cover nervous disorders. 11% cover musculoskeletal pathologies. Compared to France?<\/strong> It’s three times wider.<\/p>\n\n The numbers are growing fast<\/strong>: 300,000 prescriptions exceeded by 2024. German universities even offer courses dedicated to DiGA.<\/strong><\/p>\n\n But beware:<\/strong> only 30% of Germans know about DiGA. And 20% of prescriptions are never activated.<\/strong> So Germany has its challenges too.<\/strong> It’s just that these challenges don’t stand in the way of growth.<\/strong><\/p>\n\n In France, as in Germany, the same problem arises<\/strong>: healthcare professionals are struggling.<\/p>\n\n In France, it’s worse.<\/strong> Managing data and processing alerts is extra work. And in a context of growing medical deserts, who will absorb it?<\/strong> Doctors ask, “Who will free up my time?”<\/p>\n\n Germany responds in part with training.<\/strong> Specialized. Large-scale. This is the key differentiator.<\/strong><\/p>\n\n The French PECAN<\/a> program is a case in point.<\/strong><\/p>\n\n Since 2023:<\/strong> 10 applications submitted. 3 favorable opinions.<\/strong> All for remote surveillance.<\/p>\n\n This selectivity guarantees quality.<\/strong> But it also stifles innovation. So the Collectif T\u00e9l\u00e9surveillance M\u00e9dicale proposes an alternative<\/strong>: hybrid methodologies.<\/p>\n\n Combine real-life data, user feedback and population performance indicators.<\/strong> Recognize that digital devices have an organizational impact<\/strong> that goes beyond traditional biomedical criteria.<\/p>\n\n Why is this important?<\/strong> Because remote monitoring isn’t just an app. It’s a reorganization of the entire care flow.<\/strong><\/p>\n\n Firstly, to make things more flexible without compromising on rigor.<\/strong><\/p>\n\n Germany shows that temporary care speeds up patient access.<\/strong> And you collect the real data at the same time.<\/strong> PECAN has started this. We need to expand.<\/strong><\/p>\n\n Simplify eligibility criteria for premium packages, too.<\/strong> Less administrative granularity. More real access. <\/p>\n\n Secondly, to equip professionals.<\/strong><\/p>\n\n Digital health delegates” already exist. Redirecting 30% of our efforts to remote monitoring would change everything.<\/strong> Continuing education. Medical school modules. Coaching in the field. <\/p>\n\n France and Germany have signed a<\/strong> cooperation agreement<\/strong> on theevaluation of digital medical devices.<\/strong> Objective:<\/strong> harmonization. Mutual recognition. Accelerated market access. <\/p>\n\n Key deadline:<\/strong> revision of generic remote monitoring lines in **2026 by the CNEDiMTS<\/a><\/strong>.<\/p>\n\n It’s now or never.<\/strong> Integrate feedback. Adapt the framework. Take action. <\/p>\n\n Recognized medical excellence. Cutting-edge technological innovation. High-performance social protection system. France has it all.<\/strong><\/p>\n\n What’s missing:<\/strong> reconciling scientific rigor and operational pragmatism. Draw inspiration from Germany.<\/strong> Preserve French specificities.<\/p>\n\n Millions of chronic patients are waiting.<\/strong> It’s not just a technical issue. It’s a care organization issue.<\/strong><\/p>\n\n For MedTech, it’s crystal clear: companies that navigate well in this evolving context win.<\/strong> Anticipate regulatory relaxations. Develop solutions tailored to professionals. Capitalize on potential. <\/p>\n\n Let’s talk about your context. A quick 30-minute consultation<\/strong> to identify your real regulatory and commercial challenges.<\/p>\n\n \ud83d\udc49 Schedule a consultation<\/strong><\/a><\/p>\n\n Download our free strategic reports:<\/p>\n\n \ud83d\udce5 Download your free reports \u2192 Blueprint MedTech<\/a><\/p>\n\n![\"\"](\"https:\/\/juliashift.eu\/wp-content\/uploads\/2025\/08\/20251109_1234_France-vs-Germany-Healthcare_simple_compose_01k9m68g2df7bsr3j1dywxwcx2-1-1024x683.png\")
<\/figure>\n\n
\n\nFrance: paralyzing austerity<\/h2>\n\n
\n
\n\nGermany: pragmatism that works<\/h2>\n\n
\n\nThe real stumbling block: doctors, not patients<\/h2>\n\n
\n\nEvaluation: the French bottleneck<\/h2>\n\n
\n\nHow to unlock the French market<\/h2>\n\n
\n\n
\n\nStrong signal: Franco-German agreement June 2025<\/h2>\n\n
\n\nFrance has the assets, but not the strategy<\/h2>\n\n
\n\nTo find out more<\/h2>\n\n
\n
\n\nAre you developing a remote surveillance solution?<\/h2>\n\n
\n\n\ud83c\udfaf Going further<\/h3>\n\n
Are you structuring a MedTech fundraiser?<\/strong><\/h4>\n\n
\n
\n\nAbout the author<\/h3>\n\n